Allogene Therapeutics shares rise 4.09% intraday after Sumitomo Pharma and RACTHERA submit application for Parkinson's disease treatment.

martes, 5 de agosto de 2025, 10:51 am ET1 min de lectura
ALLO--
Allogene Therapeutics, Inc. rose 4.09% in intraday trading, driven by positive news from its partner Sumitomo Pharma. Sumitomo Pharma and RACTHERA announced the submission of a manufacturing and marketing authorization application for allogeneic iPS cell-derived dopaminergic neural progenitor cells in Japan, targeting the improvement of motor functions in advanced Parkinson's disease patients. Additionally, Sumitomo Pharma reported strong momentum for CASGEVY®, with over 75 authorized treatment centers activated globally and significant progress in clinical trials for CTX310™ and CTX320™.

Allogene Therapeutics shares rise 4.09% intraday after Sumitomo Pharma and RACTHERA submit application for Parkinson's disease treatment.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios